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EDITORIALNovel Biomarkers Associated With the Outcome of
Interferon-Based Hepatitis C Virus Therapyhe past 25 years since the discovery of hepatitisTC virus (HCV) have been marked by signiﬁcant
advances in both understanding the biology of the virus
and its interactions with the human host as well as
developing treatment strategies that now allow a majority
of patients to be cured. Combination therapy consisting of
pegylated interferon-a (IFNa) 2a/2b and ribavirin was the
standard of care for treating hepatitis C for almost a decade
until the approval of ﬁrst generation NS3/4A protease in-
hibitors in 2011.1 A variety of host factors that inﬂuence
the outcome of IFN-based treatment regimens have been
identiﬁed and established as predictors for the achi-
evement of a sustained virological response (SVR). The
best-characterized host factors are single-nucleotide poly-
morphisms within the interleukin 28B (IL28B) gene locus
that are associated with an approximately twofold change
in treatment response.2 Other patient characteristics that
inﬂuence treatment outcome, such as insulin resistance,
hepatic steatosis, liver ﬁbrosis, and patient age, have been
described, but their role as a predictor for SVR is less well
characterized.3
In the search for biochemical markers that can predict
the outcome of IFN-based therapies, several studies identi-
ﬁed baseline low-density lipoprotein (LDL) levels to posi-
tively correlate with SVR rates.4,5 The knowledge that the
HCV life cycle is closely tied to the hepatic lipid pathway has
resulted in the identiﬁcation of several potential treatment
targets, but the link between HCV replication and LDL in
particular was not obvious.6
Based on their previous observation that oxidized LDL
(oxLDL) acts as an HCV entry inhibitor by disrupting the
interaction between HCV and one of its entry factors,
scavenger receptor class B member I (SR-BI), Solbach et al7
analyzed the oxLDL levels of 379 patients from the INDIV-2
study chronically infected with HCV genotype 1. The authors
demonstrated that oxLDL serum baseline levels were an
independent predictor of SVR in IFN-based treatment regi-
mens. Area under the receiver operating characteristic
curve values of oxLDL and LDL were not statistically
signiﬁcantly different, so both parameters are largely
equivalent predictors of SVR, adding to the appeal of these
ﬁndings in a clinical setting because LDL is a routine
parameter unlike oxLDL.
As a next step, Solbach et al addressed how the corre-
lation between oxLDL and SVR could be explained. They
hypothesized that (1) elevated oxLDL levels may result from
an ongoing inﬂammatory, antiviral immune response, (2)
oxLDL might enhance the antiviral effect of exogenous IFN,
or (3) oxLDL may reduce the infection of new hepatocytes
during IFN treatment, thereby enhancing the clearance of
infected cells.CelluThey were able to rule out their ﬁrst hypothesis, as
there was no correlation between oxLDL and serum alanine
aminotransferase or serum ferritin levels, markers of
hepatic inﬂammation and systemic inﬂammation, respec-
tively. To test their second hypothesis, Solbach et al
measured HCV replication in vitro as a function of pegy-
lated IFN concentration in the presence or absence of
oxLDL using genotype 1b and 2a subgenomic replicons and
cell culture-produced HCV. As they did not observe a sig-
niﬁcant difference between the two tested conditions, they
concluded that oxLDL does not alter IFN sensitivity in their
experimental system.
Finally, the authors found that oxLDL-treated cells, but
not LDL-treated cells, showed a signiﬁcant inhibition in the
spread of HCV to adjacent cells compared with untreated
control cells. Interestingly, when reanalyzing the data of
their patient cohort, they observed a modest but signiﬁcant
correlation between oxLDL serum levels and the rate of
infected cell loss, which is thought to be an important pre-
dictor for treatment outcome.
Clinicians, especially in resource-limited environments,
may take oxLDL or LDL serum levels into consideration for
treatment decisions although these predictors are unlikely
to broadly affect such decisions in real-world settings. The
signiﬁcance of this study lies more in adding to our
understanding the pathophysiology of HCV. The authors’
data indicate that oxLDL is likely not only the molecule
responsible for the previously observed positive correlation
between LDL serum levels and SVR in IFN-based treatment
regimens, but also that this effect is possibly due to an
oxLDL-mediated inhibition of HCV cell-to-cell spread. Taken
together with their previous observation that oxLDL
interferes with the interaction of HCV and its entry factor
SR-BI, the authors provide additional evidence that SR-BI
may be needed for the cell-to-cell spread of HCV, which
could have implications for the further development of HCV
entry inhibitors.
MARKUS VON SCHAEWEN
ALEXANDER PLOSS
Department of Molecular Biology
Princeton University
Princeton, New JerseyReferences
1. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C.
Lancet 2015;385:1124–1135.
2. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in
IL28B predicts hepatitis C treatment-induced viral
clearance. Nature 2009;461:399–401.lar and Molecular Gastroenterology and Hepatology 2015;1:257–258
258 von Schaewen and Ploss Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 33. Imran M, Manzoor S, Ashraf J, et al. Role of viral and host
factors in interferon based therapy of hepatitis C virus
infection. Virol J 2013;10:299.
4. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Pre-
dictors of response of US veterans to treatment for the
hepatitis C virus. Hepatology 2007;46:37–47.
5. Economou M, Milionis H, Filis S, et al. Baseline choles-
terol is associated with the response to antiviral therapy
in chronic hepatitis C. J Gastroenterol Hepatol 2008;
23:586–591.
6. Bassendine MF, Sheridan DA, Felmlee DJ, et al. HCV and
the hepatic lipid pathway as a potential treatment target.
J Hepatol 2011;55:1428–1440.
7. Solbach P, Westhaus S, Deest M, et al. Oxidized low-
density lipoprotein is a novel predictor of interferonresponsiveness in chronic hepatitis C infection. Cell Mol
Gastroenterol Hepatol 2015;1:285–294.
Correspondence
Address correspondence to: Alexander Ploss, PhD, Department of Molecular
Biology, Princeton University, 110 Lewis Thomas Laboratory, Washington
Road, Princeton, New Jersey 08544. e-mail: aploss@princeton.edu; fax: (609)
258-1701.
Acknowledgment
The authors thank Jenna Gaska for critical discussion of the manuscript.
Conﬂicts of interest
The authors disclose no conﬂicts.
© 2015 The Authors. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
2352-345X
http://dx.doi.org/10.1016/j.jcmgh.2015.03.005
